120 related articles for article (PubMed ID: 29246820)
1. Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study.
Samaras P; Rütti MF; Seifert B; Bachmann H; Schanz U; Eisenring M; Renner C; Susanne Müller AM; Schmidt A; Mischo A; Fuchs I; Bargetzi M; Manz MG; Stupp R; Petrausch U; Stenner-Liewen F
Biol Blood Marrow Transplant; 2018 Apr; 24(4):694-699. PubMed ID: 29246820
[TBL] [Abstract][Full Text] [Related]
2. Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.
Maul JT; Stenner-Liewen F; Seifert B; Pfrommer S; Petrausch U; Kiessling MK; Schanz U; Nair G; Mischo A; Taverna C; Schmidt A; Bargetzi M; Stupp R; Renner C; Samaras P
J Clin Apher; 2017 Feb; 32(1):21-26. PubMed ID: 27001243
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies.
André M; Baudoux E; Bron D; Canon JL; D'Hondt V; Fassotte MF; D'Hondt L; Fillet G; Humblet Y; Jerusalem G; Vermeulen P; Symann M; Beguin Y
Transfusion; 2003 Jan; 43(1):50-7. PubMed ID: 12519430
[TBL] [Abstract][Full Text] [Related]
5. Lenograstim versus filgrastim in mobilization before autologous hematopoietic stem cell transplantation in patients with multiple myeloma and lymphoma - Single center experience.
Sarıcı A; Erkurt MA; Bahçecioğlu ÖF; Biçim S; Berber İ; Gök S; Kaya E; Özgül M; Kuku İ
Transfus Apher Sci; 2021 Aug; 60(4):103127. PubMed ID: 33863669
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma.
de Mel S; Chen Y; Lin A; Soh TG; Ooi M; Yap ES; Donato LKS; Halim NAA; Mah J; Lim K; Poon LM; Tan B; Yelly ; Lim HL; Koh LP; Tai BC; Chen Z; Chng WJ; Gopalakrishnan SK; Tan LK
Hematol Oncol Stem Cell Ther; 2018 Dec; 11(4):225-232. PubMed ID: 29705566
[TBL] [Abstract][Full Text] [Related]
7. Filgrastim alone versus cyclophosphamide and filgrastim for mobilization in multiple myeloma patients.
Sarıcı A; Erkurt MA; Bahçecioğlu ÖF; Gök S; Kuku İ; Biçim S; Berber İ; Kaya E; Özgül M
Transfus Apher Sci; 2021 Aug; 60(4):103159. PubMed ID: 34034961
[TBL] [Abstract][Full Text] [Related]
8. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.
Kuan JW; Su AT; Wong SP; Sim XY; Toh SG; Ong TC; Rajasuriarr JS; Lim SH; Guan YK; Liew HK; Liew PK; Tan JT; Kori AN; Cheng YY; Tan SM; Chang KM
Transfus Apher Sci; 2015 Oct; 53(2):196-204. PubMed ID: 25910537
[TBL] [Abstract][Full Text] [Related]
9. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma.
Goldschmidt H; Hegenbart U; Haas R; Hunstein W
Bone Marrow Transplant; 1996 May; 17(5):691-7. PubMed ID: 8733683
[TBL] [Abstract][Full Text] [Related]
10. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
11. Successful hematopoietic stem cell mobilization with vinorelbine and filgrastim in germ cell tumor.
Carneiro-Silva FA; Brunetta DM; Kaufman J; Leitão JPV; Barroso KSN; Barbosa SAT; Carlos LMB; Barroso-Duarte F
Clin Exp Med; 2017 Aug; 17(3):417-418. PubMed ID: 27165295
[TBL] [Abstract][Full Text] [Related]
12. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A
Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573
[TBL] [Abstract][Full Text] [Related]
13. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.
Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM
Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264
[TBL] [Abstract][Full Text] [Related]
14. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
[TBL] [Abstract][Full Text] [Related]
15. A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant.
Abhyankar S; Lubanski P; DeJarnette S; Merkel D; Bunch J; Daniels K; Aljitawi O; Lin T; Ganguly S; McGuirk J
J Clin Apher; 2016 Dec; 31(6):559-563. PubMed ID: 26939585
[TBL] [Abstract][Full Text] [Related]
16. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
Skopec B; Skerget M; Zontar D; Zadnik V; Zver S
Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
[TBL] [Abstract][Full Text] [Related]
17. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets.
Chin-Yee IH; Keeney M; Stewart AK; Belch A; Bence-Buckler I; Couban S; Howson-Jan K; Rubinger M; Stewart D; Sutherland R; Paragamian V; Bhatia M; Foley R
Bone Marrow Transplant; 2002 Dec; 30(12):851-60. PubMed ID: 12476276
[TBL] [Abstract][Full Text] [Related]
18. Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.
Abid MB; De Mel S; Abid MA; Yap ES; Gopalakrishnan SK; Chen Y; Yuen YC; Wong HC; Lin A; Poon LM; Koh LP; Chng WJ; Tan LK
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):174-179. PubMed ID: 29398647
[TBL] [Abstract][Full Text] [Related]
19. Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease.
Tormey CA; Snyder EL; Cooper DL
Transfusion; 2008 Sep; 48(9):1930-3. PubMed ID: 18513256
[TBL] [Abstract][Full Text] [Related]
20. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
